

From the INTERNATIONAL BUREAU

PCTNOTIFICATION CONCERNING
TRANSMITTAL OF COPY OF INTERNATIONAL
APPLICATION AS PUBLISHED OR REPUBLISHED

To:

AOKI, Atsushi
A. AOKI, ISHIDA & ASSOCIATES, Toranomom 37 Mori Bldg.,
5-1, Toranomom 3-chome, Minato-ku, Tokyo
1058423
JAPON

12

Date of mailing (day/month/year) 17 February 2005 (17.02.2005)		
Applicant's or agent's file reference P817-PCT		IMPORTANT NOTICE
International application No. PCT/JP2004/011812	International filing date (day/month/year) 11 August 2004 (11.08.2004)	Priority date (day/month/year) 11 August 2003 (11.08.2003)
Applicant CHUGAI SEIYAKU KABUSHIKI KAISHA et al		

The International Bureau transmits herewith the following documents:

- ☒ copy of the international application as published by the International Bureau on 17 February 2005 (17.02.2005) under No. WO 2005/014651
- ☐ copy of international application as republished by the International Bureau on under No. WO
For an explanation as to the reason for this republication of the international application, reference is made to INID codes (15), (48) or (88) (as the case may be) on the front page of the attached document.

BEST AVAILABLE COPY

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Yoshiko Kuwahara

Facsimile No.+41 22 740 14 35

Facsimile No.+41 22 338 90 90

(19) 世界知的所有権機関
国際事務局



(43) 国際公開日
2005年2月17日 (17.02.2005)

PCT

(10) 国際公開番号
WO 2005/014651 A1

(51) 国際特許分類: C07K 16/30, C12N 15/12, C12P 21/08

(21) 国際出願番号: PCT/JP2004/011812

(22) 国際出願日: 2004年8月11日 (11.08.2004)

(25) 国際出願の言語: 日本語

(26) 国際公開の言語: 日本語

(30) 優先権データ:
特願2003-207165 2003年8月11日 (11.08.2003) JP

(71) 出願人 (米国を除く全ての指定国について): 中外製薬株式会社 (CHUGAI SEIYAKU KABUSHIKI KAISHA) [JP/JP]; 〒1158543 東京都北区浮間5丁目5番1号 Tokyo (JP).

(72) 発明者; および

(75) 発明者/出願人 (米国についてのみ): 土屋 政幸 (TSUCHIYA, Masayuki) [JP/JP]; 〒4128513 静岡県御殿場市駒門1丁目135番地 中外製薬株式会社内 Shizuoka (JP). 飯島 成幸 (IIJIMA, Shigeyuki) [JP/JP]; 〒4128513 静岡県御殿場市駒門1丁目135番地 中外製薬株式会社内 Shizuoka (JP). 周郷 泉 (SUGO, Izumi) [JP/JP]; 〒4128513 静岡県御殿場市駒門1丁目135番地 中外製薬株式会社内 Shizuoka (JP). 杉本 正道 (SUGIMOTO, Masamichi) [JP/JP]; 〒2478530 神奈川県鎌倉市梶原200 中外製薬株式会社内 Kanagawa (JP).

(74) 代理人: 青木 篤, 外(AOKI, Atsushi et al.); 〒1058423 東京都港区虎ノ門三丁目5番1号 虎ノ門37森ビル 青和特許法律事務所 Tokyo (JP).

(81) 指定国 (表示のない限り、全ての種類の国内保護が可能): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) 指定国 (表示のない限り、全ての種類の広域保護が可能): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), ユーラシア (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), ヨーロッパ (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

添付公開書類:
— 国際調査報告書

2文字コード及び他の略語については、定期発行される各PCTガゼットの巻頭に掲載されている「コードと略語のガイダンスノート」を参照。

(54) Title: SUGAR CHAIN-MODIFIED ANTI-HM1.24 ANTIBODY

(54) 発明の名称: 糖鎖改変抗HM1.24抗体

(57) Abstract: Sugar chain modification makes it possible to provide the following antibody having enhanced antibody-dependent cellular cytotoxicity (ADCC), i.e., an antibody having a sugar chain free from an antibody against HM1.24 antigen (anti-HM1.24 antibody, more specifically speaking, α -1,6 core fucose), an antibody having a sugar chain having a bisecting N-acetylglucosamine (GlcNAc) structure, or an antibody having a sugar chain free from α -1,6 core fucose and having a sugar chain having a bisecting N-acetylglucosamine (GlcNAc) structure.

(57) 要約: 糖鎖の改変により抗体依存性細胞傷害性 (Antibody-Dependent Cellular Cytotoxicity; ADCC) が増強された、HM1.24抗原に対する抗体 (抗HM1.24抗体、具体的には α -1,6コアフコース (α -1,6corefucose) を含まない糖鎖を有する抗体、バイセクティング (bisecting) N-アセチルグルコサミン (GlcNAc) 構造を有する糖鎖を有する抗体、又は α -1,6コアフコース (α -1,6corefucose) を含まない糖鎖を有し、且つバイセクティング (bisecting) N-アセチルグルコサミン (GlcNAc) 構造を有する糖鎖を有する抗体。

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/011812

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl⁷ C07K16/30, C12N15/12, C12P21/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl⁷ C07K16/30, C12N15/12, C12P21/08

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
BIOSIS/WPI (DIALOG)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98/37913 A1 (Chugai Pharmaceutical Co., Ltd.), 03 September, 1998 (03.09.98), Full text & JP 10-298106 A & EP 972524 A1 & US 2002/034507 A1	1-12
Y	JP 10-286088 A (Chugai Pharmaceutical Co., Ltd.), 27 October, 1998 (27.10.98), Full text & WO 98/35698 A1 & EP 997152 A1	1-12
Y	WO 02/31140 A1 (Kyowa Hakko Kogyo Co., Ltd.), 18 April, 2002 (18.04.02), Full text & EP 1331266 A1	1-12

☒ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
20 October, 2004 (20.10.04)

Date of mailing of the international search report
09 November, 2004 (09.11.04)

Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

Form PCT/ISA/210 (second sheet) (January 2004)

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/011812

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JP 2002-512014 A (UNAMA, Pablo), 23 April, 2002 (23.04.02), Full text & WO 99/54342 A1	1-12
Y	WO 02/79255 A1 (IDEC PHARMACEUTICALS Co.), 10 October, 2002 (10.10.02), Full text. (Family: none)	1-12

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/011812

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
 - a. type of material
 - ☒ a sequence listing
 - ☐ table(s) related to the sequence listing
 - b. format of material
 - ☐ in written format
 - ☒ in computer readable form
 - c. time of filing/furnishing
 - ☐ contained in the international application as filed
 - ☒ filed together with the international application in computer readable form
 - ☐ furnished subsequently to this Authority for the purposes of search
2. ☒ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments: